Compare Gogoro Inc (GGR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gogoro Inc vs Neurocrine Biosciences Inc — how do they compare? Gogoro Inc trades at $3.15 (market cap $56.21M), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 255.5× Gogoro Inc's market cap, and Gogoro Inc is more actively traded (14,026 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Gogoro Inc for 14 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GGR | NBIX | |
|---|---|---|
Market Cap | $56.21M | $14.36B |
Volume | 14,026 | 1,237,180 |
Sector | Consumer Cyclical | Health |
52-Week High | $5.15 | $185.50 |
52-Week Low | $2.20 | $123.10 |
Typical Hold Time | 14 Days | 23 Days |
Enterprise Value | $342.65M | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gogoro (GGR) trades at $3.15, up 5.35% today, but faces bearish technical signals and weak profitability, with a net loss of $79.97M in 2025. Revenue grew modestly to $281.48M, yet margins remain negative. Recent news highlights board changes and a $61.8M equity investment, signaling internal restructuring efforts. The stock shows oversold conditions with an RSI of 27.68, but moving averages indicate a downtrend.
The outlook is cautious due to persistent losses and high debt-to-asset ratio of 60%, though low valuation ratios (P/S 0.16, P/B 0.5) may attract value investors. Risks include execution challenges and competitive pressures. Analysts are neutral with 100% hold ratings, reflecting uncertainty about near-term turnaround.
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
